- $940.35m
- $3.49bn
- $2.73bn
U.S. STOCKS ON THE MOVE-Bath & Body Works, Avis Budget, Cerebras
U.S. STOCKS ON THE MOVE-Boundless Bio, Galectin, UniQure
U.S. STOCKS ON THE MOVE-Chipmakers, CDW, Accenture
QuidelOrtho appoints new CFO; shares fall
U.S. RESEARCH ROUNDUP-ARM Holdings, CDW, Doordash
QuidelOrtho misses Q1 revenue estimates, cuts FY outlook
Brief: QuidelOrtho Q1 EPS USD -1.35
Spanish stocks - Factors to watch on April 23
U.S. RESEARCH ROUNDUP- CME Group, M&T Bank, PNC Financial Services
Brief: Quidelortho Announces Preliminary Revenue For The First Quarter 2026 And Provides Update On Full-Year 2026 Guidance
In vitro diagnostics firm QuidelOrtho beats Q3 revenue expectations
Brief: QuidelOrtho Receives FDA 510(k) Clearance for VITROS Immunodiagnostic Products hs Troponin I Assay
Brief: QuidelOrtho Completes Debt Refinancing
Brief: QuidelOrtho Welcomes Erich Wolff As EVP, Strategy & Corporate Development
QuidelOrtho Corp reports results for the quarter ended June 30 - Earnings Summary
QuidelOrtho Q2 revenue falls but beats expectations
Brief: Quidelortho And Bühlmann Laboratories AG Announce Availability Of Fecal Calprotectin (Fcal®) Turbo And Fecal Pancreatic Elastase (Fpela®) Turbo Assays On Vitros™ Systems As A Microtip™ Partnership Assay (Mpa)
Brief: Quidelortho Strengthens Leadership Team With Appointments Of Senior Vice Presidents For Global Quality And Clinical & Regulatory Affairs
U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global